



TITOLO
(maiuscolo)

Data Collaboration Driving CDMO Excellence in Life Science

Autore (i)

Ente
di appartenenza

Riassunto

Carattere: ARIAL
Corpo: 10
Interlinea: 1

The role of contract development and manufacturing organizations (CDMOs) is increasing in access to safe and affordable medications. Contract manufacturing is accelerating, with analysts predicting the market reaching \$330.36 billion by 2029.

CDMOs provide essential flexibility, economies of scale and the speed-to-market innovators need. Currently, 72% of pharmaceutical companies outsource at least part of their drug development and manufacturing processes. Small and mid-sized life science firms continue to be responsible for an expanding portion of new drugs, especially advanced biopharmaceuticals in the pipeline. Selecting the best contract partner to fit the drug's profile is critical to drug strategy and better patient outcomes.

Data collaboration, including valuable formula and process data, and transparency among partners is a fundamental aspect of drug development and increasingly mandatory when it comes to CDMO selection. The challenge is to safeguard existing technology investments while easily adding capacity and relevant data access across systems to share with clients.

Technology suppliers can help contractors meet the data collaboration challenge with a platform-based approach built around core digital technologies encompassing the processing and manufacturing ecosystem.

- DCS with integrated safety systems for process control
- Manufacturing excellence platforms providing MES functionality for batch execution, visualization and history
- Quality management systems for efficient cloud-based quality and compliance management
- Additional capabilities including warehouse management and track and trace

Data collaboration is essential to compliant contract operations, and the demand for real-time data collaboration will only expand. Drug product development requires secure access and interrogation of current and past product data, and quality trends from contract partners on demand. With the right digital tools and better access to vital data, life science companies and their CDMO partners will be able to continuously improve operational efficiencies, enhance quality control and predictive maintenance, accelerate innovation and ultimately deliver more effective treatments to patients.

Objectives

- Illustrate the growth and role of CDMOs in life science manufacturing
- Understand the clients' perceived trade-offs in collaborating with CDMOs
- Review what digitalization technologies enable the best data collaboration
- Reveal the benefits of data collaboration between CDMOs and their clients

Mirko Bocassini mirko.bocassini@honeywell.com +39 3421898996

IMPORTANTE: inviare il testo in formato (word o pdf) editabile e NON in formato immagine.

Autore di riferimento da contattare per ulteriori informazioni:

Nome e Cognome: Mirko Bocassini

E-mail: _____